Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;42(2):106-111.
doi: 10.1002/phar.2653. Epub 2021 Dec 20.

Tacrolimus time in therapeutic range and long-term outcomes in heart transplant recipients

Sarah K Adie  1 , Abbas Bitar  2 , Matthew C Konerman  2 , Michael P Dorsch  3 , Chris A Andrews  4 , Kristen Pogue  1 , Jeong M Park  1   3
Affiliations

Tacrolimus time in therapeutic range and long-term outcomes in heart transplant recipients

Sarah K Adie et al. Pharmacotherapy. 2022 Feb.

Abstract

Study objective: Little is known about the association between tacrolimus time in therapeutic range (TTR) within the guideline-recommended targets and heart transplant (HT) patient outcomes. This study evaluated the association of early tacrolimus TTR with rejection and other clinical outcomes during an extended follow-up after HT.

Design: This was a single-center retrospective cohort study.

Setting: The study was conducted at Michigan Medicine (1/1/2006-12/31/2017).

Patients: HT recipients ≥18 years of age were included.

Measurement: The primary end point was the effect of tacrolimus TTR on time to rejection over the entire follow-up period.

Main results: A total of 137 patients were included with a median follow-up of 53 months. Based on the median TTR of 58%, the patients were divided into the low tacrolimus TTR (n = 68) and high tacrolimus TTR (n = 69) cohort. The high tacrolimus TTR was associated with a significantly lower risk of rejection compared to the low tacrolimus TTR cohort (hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.41-0.98; p = 0.04). A post hoc analysis revealed associations between rejection and TTR when high and low TTR groups were created at different levels. TTR <30% was associated with a 7-fold higher risk of rejection (HR 7.56; 95% CI 1.76-37.6; p < 0.01) and TTR >75% was associated with a 77% lower risk of rejection (HR 0.23; 95% CI 0.08-0.627; p < 0.01).

Conclusions: Patients in the higher tacrolimus TTR cohort had a lower risk of rejection. We observed correlations between higher risk of rejection with TTR <30% and lower risk of rejection with TTR >75%. Future studies should focus on validating the optimal TTR cutoff while also exploring a cutoff to delineate high-risk patients for which early interventions to improve tacrolimus TTR may be beneficial.

Keywords: heart transplant; tacrolimus; time in therapeutic range.

PubMed Disclaimer

References

REFERENCES

    1. Lund LH, Edwards LB, Dipchand AI, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. J Hear Lung Transplant. 2016;35(10):1158-1169. doi:10.1016/j.healun.2016.08.017
    1. Penninga L, Møller CH, Gustafsson F, Steinbrüchel DA, Gluud C. Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials. Eur J Clin Pharmacol. 2010;66(12):1177-1187. doi:10.1007/s00228-010-0902-6
    1. Costanzo MR, Costanzo MR, Dipchand A, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Hear Lung Transplant. 2010;29(8):914-956. doi:10.1016/j.healun.2010.05.034
    1. Baker WL, Steiger S, Martin S, et al. Association between time-in-therapeutic tacrolimus range and early rejection after heart transplant. Pharmacother J Hum Pharmacol Drug Ther. 2019;39(5):609-613. doi:10.1002/phar.2262
    1. Ensor CR, Iasella CJ, Harrigan KM, et al. Increasing tacrolimus time-in-therapeutic range is associated with superior one-year outcomes in lung transplant recipients. Am J Transplant. 2018;18(6):1527-1533. doi:10.1111/ajt.14723

LinkOut - more resources